TrialLancet (London, England)2011

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial.

Roy S Herbst et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.